Development of UK generics market assessed by new report

The UK generics market has changed quite drastically during the past few years, notes a new report from industry intelligence group RNCOS. If we look at the UK generic market some 15 years ago, it was largely a national market comprised of domestic manufacturers, many of whom were owned by originator companies, who then divested themselves of these small local national businesses, it says.

This divestment created an independent national market in the UK until these companies were bought up by growing multinational generic companies. This created today’s structure, where the greatest proportion of generic medicines is made by the global businesses, such as Teva, Sandoz, Actavis, Mylan, etc. Due to the presence of several generics manufacturers, revenue generated by generics market in the UK is anticipated to expand at a compound annual growth rate (CAGR) of over 16% during 2011-2013, says RNCOS’ new research report, titled UK Generics Market Analysis.

Generics invaluable to UK government